Arsenic trioxide shows survival benefit for leukemia patients All the way through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped concur that arsenic trioxide – marketed as Trisenox, significantly improves individual survival when coupled with standard chemotherapy treatment in newly diagnosed individuals with severe promyelocytic leukemia, or APL http://sildalis.org/ http://sildalis.org . Bayard Powell, M.D., principal investigator of the analysis and professor and section mind of Hematology and Oncology at Wake Forest University Baptist INFIRMARY, presented the findings at the annual meeting of the American Society of Clinical Oncology . Nearly 600 individuals in the U.S.

As the Picker Institute hands off its objective and resources to others it is vital that this facet of Harvey Picker's legacy end up being defended and preserved. Fortunately the Gold Foundation is a reliable partner whose shared knowledge and values promise continued growth, nourishment, and of humanism in medication. In accepting the $500,000 grant, Dr. Richard I. Levin, President and CEO of the Arnold P. Gold Foundation, said, The Picker Institute has had a major impact on health care improvements, making patient-centered treatment an essential component of optimal care in this century.